Assenagon Asset Management
HBIO icon

Assenagon Asset Management’s Harvard Bioscience HBIO Stock Holding History

Assenagon Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,922
Closed -$93.1K – 1154
2025
Q4 		$93.1K Hold
13,922
– – ﹤0.01% 1135
2025
Q3 		$61K Buy
13,922
+10,242
+278% +$48.6K ﹤0.01% 1157
2025
Q2 		$16.3K Sell
3,680
-1,763
-32% -$7.37K ﹤0.01% 1148
2025
Q1 		$30.8K Sell
5,443
-1,537
-22% -$19.7K ﹤0.01% 1142
2024
Q4 		$147K Sell
6,980
-13,252
-66% -$304K ﹤0.01% 1287
2024
Q3 		$544K Sell
20,232
-2,538
-11% -$74.8K ﹤0.01% 1232
2024
Q2 		$649K Buy
22,770
+15,022
+194% +$527K ﹤0.01% 1192
2024
Q1 		$329K Hold
7,748
– – ﹤0.01% 1273
2023
Q4 		$415K Sell
7,748
-2,127
-22% -$96K ﹤0.01% 1277
2023
Q3 		$425K Sell
9,875
-3,590
-27% -$166K ﹤0.01% 1228
2023
Q2 		$739K Buy
13,465
+7,250
+117% +$398K ﹤0.01% 1045
2023
Q1 		$261K Buy
+6,215
New +$184K ﹤0.01% 1329
2022
Q4 		– Sell
-2,238
Closed -$57K – 1399
2022
Q3 		$57K Sell
2,238
-2,220
-50% -$73.4K ﹤0.01% 1305
2022
Q2 		$160K Buy
4,458
+1,393
+45% +$62.9K ﹤0.01% 1396
2022
Q1 		$190K Sell
3,065
-9,499
-76% -$562K ﹤0.01% 1363
2021
Q4 		$886K Buy
12,564
+7,028
+127% +$500K ﹤0.01% 1070
2021
Q3 		$386K Buy
+5,536
New +$441K ﹤0.01% 1103
2020
Q3 		– Sell
-23,400
Closed -$725K – 1220
2020
Q2 		$725K Buy
+23,400
New +$630K ﹤0.01% 920
2019
Q4 		– Sell
-44,035
Closed -$1.35M – 834
2019
Q3 		$1.35M Buy
44,035
+42,738
+3,295% +$1.06M 0.01% 493
2019
Q2 		$26K Sell
1,297
-6,978
-84% -$204K ﹤0.01% 981
2019
Q1 		$357K Buy
+8,275
New +$300K ﹤0.01% 847

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management's HBIO Position: Q1 2026 in Review

Assenagon Asset Management sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 13,922 shares — an estimated $93.1K sold.

Assenagon Asset Management first reported a position in HBIO in Q1 2019 and held it in 21 quarters. The position peaked at $1.35M in Q3 2019. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Assenagon Asset Management reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 13,922 Harvard Bioscience shares in Q1 2026, an estimated $93.1K.
  • Assenagon Asset Management first reported a position in Harvard Bioscience in Q1 2019 and held it in 21 quarters.
  • Assenagon Asset Management's Harvard Bioscience position peaked at $1.35M in Q3 2019.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Assenagon Asset Management's 13F filing for Q1 2026, filed 20 Apr 2026.